IRISH MEDICINES BOARD

# Notice Information: Human Medicines - Advisory 14 December 2007

## Part 1. Product Information

| | | |
|---|---|---|
| a) | Title: | EMEA recommends withdrawal of the marketing authorisations for lumiracoxib-containing medicines |
| b) | Product Name/Type: | Lumiracoxib-containing medicines-(Prexige) |
| c) | Active Substance: | Lumiracoxib |
| d) | Reference: | EMEA Press Release |
| e) | Product Classification: | Non-steroidal anti-inflammatory drug (NSAID)- COX-2 inhibitors |

## Part 2. Problem/Issue

| | | |
|---|---|---|
| a) | Problem/Issue: | Following review at EU level, withdrawal of marketing authorisations for all lumiracoxib-containing medicines has been recommended from Member States where the products are marketed (not available in Ireland), because of a risk of serious side effects affecting the liver. Lumiracoxib is a non-steroidal anti-inflammatory drug (NSAID) used for symptomatic relief in the treatment of osteoarthritis of the hip and knee. For further information, click here to read the Press Release |

## Part 3. Enquiries

| | | |
|---|---|---|
| a) | All enquiries should be made to: | Media enquiries only to: Martin Harvey Allchurch or Monika Benstetter Tel. (44-20) 74 18 84 27, E-mail press@emea.europa.eu |

## Part 4. Keywords

| | | |
|---|---|---|
| a) | Keywords: | lumiracoxib-containing medicines |